Globus Medical announces the continued growth and expansion of its orthopedic trauma product portfolio. Globus has introduced several new system extensions so far in 2024 and received 510(k) clearance from the U.S. Food and Drug Administration for its first suture-based product, TENSOR Suture Button System. Newly launched, next-generation systems include ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments, and CAPTIVATE SOLA Headless Screws. “The addition of these products to our growing orthopedic trauma portfolio signifies our continued responsiveness and dedication to surgeons and patients,” said John Mulcahy, Chief Commercial Officer and President of Orthopedics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Globus Medical price target raised to $77 from $75 at BTIG
- 3 Best Stocks to Buy Now, 8/14/2024, According to Top Analysts
- Canaccord reiterates Buy on Globus, says warning letter ‘growing pains’
- Globus Medical warning brings ‘attractive’ opportunity, says Barclays
